News

The vice chair of the American Academy of Sleep Medicine’s Clinical Practice Guidelines Task Force commented on some of the unanswered questions following the recently published guidelines for restless legs syndrome. [WATCH TIME: 3 minutes]

To date, BT-267 shows strong potential as a best-in-class LRRK2 inhibitor for Parkinson disease, with a superior safety profile, excellent pharmacokinetics, and innovative development leveraging advanced technologies and biomarker modeling.

Delaying treatment past 12 months worsens leg disability scores and leads to a more challenging disease course in CIDP patients.

The launch of lorcaserin studies in 2020 coincided with several patients starting the newly available fenfluramine, which may have contributed to challenges in enrolling enough participants.

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.

The assistant professor of neurology at the Icahn School of Medicine at Mount Sinai provided an overview of a session on exercise and migraine presented at the 2024 Scottsdale Headache Symposium. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The application is based on a large-scale phase 3 study in which blarcamesine demonstrated a significant decline in disease progression compared with placebo over a 48-week period.

Findings from a phase 2/3 study demonstrated the efficacy and safety of a higher dose regimen of nusinersen in treating spinal muscular atrophy in both treatment-naïve and previously treated patients.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on parasomnias.

Subgroup analyses revealed stronger efficacy signals in biomarker-defined groups, particularly in Caucasian participants with measurable baseline myostatin levels.

These results highlight the age range and ambulation status for which viltolarsen is a key treatment option for DMD patients amenable to exon 53 skipping.

Neurology News Network. for the week ending November 30, 2024. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 29, 2024.

Shalini Paruthi, MD, FAASM, a spokesperson for the American Academy of Sleep Medicine, provided a clinical overview on restless leg syndrome for diagnosing and tailoring treatment for patients with the condition.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Andy Berkowski, MD, PhD. [LISTEN TIME: 26 minutes]

As part of our monthly clinician spotlight, NeurologyLive® highlighted epilepsy expert Stephanie C. Randle, MD, MS, director of the Tuberous Sclerosis Complex Clinic at Seattle Children's Hospital.

Applied Therapeutics noted that it is reviewing the FDA's feedback and will request a meeting to discuss requirements for either a resubmission of the NDA or appeal of the agency's decision.

A recent multicenter study showed that dried blood spot testing for neuromyelitis optica spectrum disorder provided high accuracy and practicality in resource-limited settings.

A new study revealed stark racial and socioeconomic disparities in pediatric neuromyelitis optica spectrum disorder outcomes, underscoring the need for targeted interventions.

Over the 6-month treatment period, patients saw improvements in cataplexy frequency, excessive daytime sleepiness, cognition, and work productivity with AXS-12.

The pediatric neurologist at Duke Health and chief executive officer at Theranica talked about a remote electrical neuromodulation wearable that showed promising results for the treatment and prevention of migraine in pediatric patients. [WATCH TIME: 5 minutes]

The vice president of scientific engagement at the Alzheimer's Association discussed advancements in blood biomarker tests, their use in specialty care, and the development of clinical guidelines for broader integration.

AL002 did not meet the primary endpoint of slowing Alzheimer's clinical progression, as measured by the Clinical Dementia Rating Sum of Boxes and showed no treatment effects on secondary clinical and functional endpoints.

The cofounder and chief science officer of the Alzheimer's Drug Discovery Foundation highlighted the critical role of collaboration and innovative diagnostics for advancing Alzheimer disease care. [WATCH TIME: 4 minutes]

Over 1 year of treatment, simufilam failed to distinguish itself from placebo on the primary end points of Alzheimer’s Disease Assessment Scale-Cognitive Subscale 12 and Alzheimer’s Disease Cooperative Study-Activities of Daily Living.

The professor of neurology at the University of Pennsylvania Perelman School of Medicine provided clinical insight on a long-term safety analysis of omaveloxolone, the first FDA-approved treatment for Friedreich ataxia. [WATCH TIME: 4 minutes]

In a 76-patient cohort, HL192 was safe and well tolerated across 5 observed dose levels, with a treatment-emergent adverse event incidence that mirrored placebo.

When looking at the intersection of MS and domestic abuse, one can find hidden challenges and a need for innovative efforts to support vulnerable patients and survivors.

Here's the latest multidisciplinary multiple sclerosis (MS) research from the International Journal of MS Care.